drugset / Trial / NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
NaSingle-groupOpen-labelTreatment
Summary
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Timeline
- Start
- 2024-09-18
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emapalumab | Monoclonal antibody | — | Intravenous |
| Background | Axicabtagene Ciloleucel | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |